Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals  
10/7/2013 9:48:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn. & NEW YORK, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., formerly Rib-X Pharmaceuticals, today announced the launch a new corporate identity, an important milestone in the Company's evolution. Melinta's new strategic direction leverages the Nobel Prize-winning science developed by Rib-X's founders. To accelerate the product portfolio, the Company will be led by a new management team with experience launching and building pharmaceutical brands. The driving force behind this new strategic direction is Melinta's new lead investor, Vatera Healthcare Partners, a specialized venture capital firm with a proven ability to build successful life sciences companies. The culmination of this process is marked with the launch of Melinta Therapeutics, an organization focused on bringing novel, differentiated antibiotics to market.

Help employers find you! Check out all the jobs and post your resume.